Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.
In an addendum, the Institute now examined information subsequently submitted by the manufacturer in the commenting procedure: According to the findings, there is an indication of added benefit; however, the extent is non-quantifiable.
Mortality: data in the dossier incomplete and not interpretable
Treatment switching occurred in all three approval studies comparing sipuleucel-T with placebo, which were presented in the dossier by the manufacturer: More than two thirds of the patients in the placebo group started treatment with sipuleucel-T on progression of their disease. In both study arms, patients received chemotherapy with docetaxel on progression. The proportion of patients who received docetaxel and the time point of this treatment differed, however, and the respective information provided in the dossier was incomplete.
The study results on overall survival in the dossier could therefore not be interpreted in a meaningful way: Docetaxel has a positive effect on survival. If, for example, it is given at an earlier time point in the sipuleucel-T arm than in the control arm, lower mortality cannot be explained solely by the effect of sipuleucel-T. Then there is a risk of overestimating the effect of sipuleucel-T.
Additional analyses showed advantage in mortality
The manufacturer presented further data and sensitivity analyses on overall survival with its comment. This now led to a consistent picture in comparison with the primary analysis of the data in the dossier: According to this, the lower mortality in the sipuleucel-T arms cannot be explained solely by differences in the administration of docetaxel after progression.
However, the advantages in overall survival are accompanied by negative effects in the form of side effects: Fever, headache and chills were more frequent in patients in the sipuleucel-T arm. However, these side effects were non-serious and mainly occurred only directly after the administration of sipuleucel-T. IQWiG therefore did not downgrade the positive effect regarding mortality. The conclusion of the addendum for sipuleucel-T is therefore an indication of an added benefit with the extent "non-quantifiable".
G-BA decides on the extent of added benefit
The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the manufacturer's dossier and the IQWiG dossier assessment, the manufacturer submitted additional information in the commenting procedure. The G-BA subsequently commissioned IQWiG to assess the data subsequently submitted. IQWiG now presents this assessment in the form of an addendum. The G-BA makes a final decision on the extent of added benefit.
Explore further: Daclatasvir for hepatitis C: Hint of added benefit in genotype 4
More information: http://ift.tt/1Bba7kJ -38_Sipuleucel-T.pdf
Medical Xpress on facebook
Related Stories
Daclatasvir for hepatitis C: Hint of added benefit in genotype 4
Feb 24, 2015
Daclatasvir (trade name Daklinza) has been approved since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. According to the dossier assessment conducted by the German Institute for Quality ...
Sipuleucel-T in prostate cancer: Added benefit is not proven
Jan 08, 2015
Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. The German Institute for Quality and Efficiency ...
Vildagliptin for type 2 diabetes: No suitable data for combination with sulfonylurea
Mar 09, 2015
Vildagliptin (trade name Galvus or Jalra) has been approved since September 2007 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control. The German Institute for Quality ...
Simoctocog alfa for haemophilia A: No suitable data
Feb 20, 2015
Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...
Ledipasvir plus sofosbuvir: Hint of added benefit in certain patients
Mar 09, 2015
The drug combination of ledipasvir and sofosbuvir (trade name Harvoni) has been available since November 2014 for the treatment of chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care ...
Recommended for you
FDA panel backs Glaxo inhaler for adults, not adolescents
14 hours ago
Government health advisers say a once-a-day respiratory inhaler from GlaxoSmithKline appears safe and effective for adults with asthma, but not for adolescents.
Cholbam approved for rare metabolic disorders
Mar 18, 2015
(HealthDay)—Cholbam (cholic acid) capsules have been approved by the U.S. Food and Drug Administration to treat adults and children with bile acid synthesis disorders and peroxisomal disorders, the agency said in a news ...
Prices of cancer drugs have soared since 1995, study finds
Mar 17, 2015
The prices of leading cancer drugs have risen at rates far outstripping inflation over the last two decades, according to a new study co-authored by an MIT economist—but the exact reasons for the cost increases ...
New hepatitis C drugs will place strain on health care system
Mar 16, 2015
The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system. The prediction comes from a cost-effectiveness ...
New system for detecting adverse effects of medications using social media
Mar 16, 2015
Researchers at Carlos III Universidad de Madrid have developed a system for detecting adverse effects of pharmaceutical drugs by tracking information generated by patients on specialized blogs or social networks ...
Studies boost hopes for new class of cholesterol medicines
Mar 16, 2015
New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can greatly lower the risk for heart attacks, death and other heart-related problems.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.
In an addendum, the Institute now examined information subsequently submitted by the manufacturer in the commenting procedure: According to the findings, there is an indication of added benefit; however, the extent is non-quantifiable.
Mortality: data in the dossier incomplete and not interpretable
Treatment switching occurred in all three approval studies comparing sipuleucel-T with placebo, which were presented in the dossier by the manufacturer: More than two thirds of the patients in the placebo group started treatment with sipuleucel-T on progression of their disease. In both study arms, patients received chemotherapy with docetaxel on progression. The proportion of patients who received docetaxel and the time point of this treatment differed, however, and the respective information provided in the dossier was incomplete.
The study results on overall survival in the dossier could therefore not be interpreted in a meaningful way: Docetaxel has a positive effect on survival. If, for example, it is given at an earlier time point in the sipuleucel-T arm than in the control arm, lower mortality cannot be explained solely by the effect of sipuleucel-T. Then there is a risk of overestimating the effect of sipuleucel-T.
Additional analyses showed advantage in mortality
The manufacturer presented further data and sensitivity analyses on overall survival with its comment. This now led to a consistent picture in comparison with the primary analysis of the data in the dossier: According to this, the lower mortality in the sipuleucel-T arms cannot be explained solely by differences in the administration of docetaxel after progression.
However, the advantages in overall survival are accompanied by negative effects in the form of side effects: Fever, headache and chills were more frequent in patients in the sipuleucel-T arm. However, these side effects were non-serious and mainly occurred only directly after the administration of sipuleucel-T. IQWiG therefore did not downgrade the positive effect regarding mortality. The conclusion of the addendum for sipuleucel-T is therefore an indication of an added benefit with the extent "non-quantifiable".
G-BA decides on the extent of added benefit
The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the manufacturer's dossier and the IQWiG dossier assessment, the manufacturer submitted additional information in the commenting procedure. The G-BA subsequently commissioned IQWiG to assess the data subsequently submitted. IQWiG now presents this assessment in the form of an addendum. The G-BA makes a final decision on the extent of added benefit.
Explore further: Daclatasvir for hepatitis C: Hint of added benefit in genotype 4
More information: http://ift.tt/1Bba7kJ -38_Sipuleucel-T.pdf
Medical Xpress on facebook
Related Stories
Daclatasvir for hepatitis C: Hint of added benefit in genotype 4
Feb 24, 2015
Daclatasvir (trade name Daklinza) has been approved since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. According to the dossier assessment conducted by the German Institute for Quality ...
Sipuleucel-T in prostate cancer: Added benefit is not proven
Jan 08, 2015
Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. The German Institute for Quality and Efficiency ...
Vildagliptin for type 2 diabetes: No suitable data for combination with sulfonylurea
Mar 09, 2015
Vildagliptin (trade name Galvus or Jalra) has been approved since September 2007 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control. The German Institute for Quality ...
Simoctocog alfa for haemophilia A: No suitable data
Feb 20, 2015
Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...
Ledipasvir plus sofosbuvir: Hint of added benefit in certain patients
Mar 09, 2015
The drug combination of ledipasvir and sofosbuvir (trade name Harvoni) has been available since November 2014 for the treatment of chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care ...
Recommended for you
FDA panel backs Glaxo inhaler for adults, not adolescents
14 hours ago
Government health advisers say a once-a-day respiratory inhaler from GlaxoSmithKline appears safe and effective for adults with asthma, but not for adolescents.
Cholbam approved for rare metabolic disorders
Mar 18, 2015
(HealthDay)—Cholbam (cholic acid) capsules have been approved by the U.S. Food and Drug Administration to treat adults and children with bile acid synthesis disorders and peroxisomal disorders, the agency said in a news ...
Prices of cancer drugs have soared since 1995, study finds
Mar 17, 2015
The prices of leading cancer drugs have risen at rates far outstripping inflation over the last two decades, according to a new study co-authored by an MIT economist—but the exact reasons for the cost increases ...
New hepatitis C drugs will place strain on health care system
Mar 16, 2015
The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system. The prediction comes from a cost-effectiveness ...
New system for detecting adverse effects of medications using social media
Mar 16, 2015
Researchers at Carlos III Universidad de Madrid have developed a system for detecting adverse effects of pharmaceutical drugs by tracking information generated by patients on specialized blogs or social networks ...
Studies boost hopes for new class of cholesterol medicines
Mar 16, 2015
New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can greatly lower the risk for heart attacks, death and other heart-related problems.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment